PPD

Clinical Research Headquarters
929 North Front Street
Wilmington
North Carolina
28401
United States

Tel: 910-251-0081

Website: https://www.ppd.com/

2023 Best Places to Work
Show jobs for this employer

About PPD

PPD is part of Thermo Fisher Scientific. As the world’s leader in serving science, our professionals develop critical solutions—and build rewarding careers. We offer services and products that help customers around the globe in laboratories and clinics, on production lines and out in the field. ​

We’re a driving force in the research, healthcare, industrial and applied markets, generating more $35 billion in annual revenue. No other company can match our range of customer touch points—technologically, geographically or commercially. We help customers in finding cures for cancer, protecting the environment, bringing medicines to market, making sure our food is safe and moving forward with thousands of important projects that improve millions of lives.

Stock Symbol: TMO

Stock Exchange: NYSE

Find PPD on social media:

Facebook Twitter

Find PPD Careers on social media:

Instagram Twitter

We All Have Our Why | PPD

446 articles about PPD

  • Further expands service offering to pharma and biotech customers - Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry - Adds highly complementary services for the company's fastest growing end market

  • AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 1b/2a clinical trial

  • PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, April 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its first quarter 2021 financial results.

  •   PPD Named a Leader in Digital Clinical Trial Solutions by ISG   Recognized for comprehensive strengths in the design, deployment of decentralized solutions

  • Rare Disease Day takes place on the last day of February because it is a month known for having a “rare” number of days.

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, will present virtually at the Barclays Global Healthcare Conference. David Simmons, chairman and CEO, and Chris Scully, CFO, are scheduled to participate in a fireside chat on Tuesday, March 9, 2021, at 3:35 p.m. (U.S. Eastern Time).

  • PPD, Inc., a leading global contract research organization, reported its financial results for the fourth quarter and full year ended December 31, 2020.

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has been awarded Defense Health Agency funds to support a five-year Research Project Award (RPA) to develop and execute an adaptive platform clinical research trial of drug interventions to treat post-traumatic stress disorder (PTSD).

  • PPD, Inc. has been recognized for the 10th consecutive year as one of the leading U.S. businesses for employee learning and development.

  • AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 2 clinic trial

  • PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, Feb. 24, 2021, at 9 a.m. (U.S. Eastern Time) to discuss its fourth quarter and full-year 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD’s website at https://investors.ppd.com .

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. David Simmons, chairman and CEO, and Chris Scully, CFO, are scheduled to present on Monday, Jan. 11, 2021, at 2:50 p.m. (U.S. Eastern Time). A live and archived webcast of the presentation, along with accompanying slides, will be accessible for up to 30 days through

  • PPD, Inc. (Nasdaq: PPD ) has been named one of the Best Workplaces in Greater China™ by Great Place to Work ® , a global authority on high-trust, high-performance workplace cultures that provides executive advisory and culture consulting services to businesses, nonprofits and government agencies. The honor builds on the announcement by PPD to adopt a new Mandarin company name in China to reflect its continuing growth

  • PPD, Inc. (Nasdaq: PPD ), was named the Clinical Research Company of the Year for winning multiple awards at the PharmaTimes Clinical Researcher of the Year competitions. In addition to PPD winning the highest honor at the PharmaTimes International Clinical Researcher of the Year 2020 virtual awards ceremony, individual PPD clinical researchers won gold and bronze in both the Clinical Research Associate (CRA) and

  • PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Oct. 28, 2020, at 9 a.m. (U.S. Eastern Time) to discuss its third quarter 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging onto the investors section of PPD’s website at https://investors.ppd.com . An archive copy of the webcast w

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has achieved the internationally recognized information security certification ISO/IEC 27001:2013, demonstrating the company’s commitment to ensuring the protection of its customers’ data. ISO/IEC 27001:2013 is an information security standard published by the International Organization for Standardization (ISO), the world’s largest develop

  • PPD, Inc., a leading global contract research organization, announced the pricing of an underwritten public offering by certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., of 38,000,000 shares of the Company’s common stock at a price to the public of $32.25 per share.

  • PPD, Inc. (Nasdaq: PPD ), has been recognized as a top employer in Bulgaria, adding to the global contract research organization’s growing list of accolades as an employer of choice around the world. PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. The organization sel

  • PPD, Inc. announced that certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., have commenced an underwritten public offering of 38,000,000 shares of the Company’s common stock pursuant to a registration statement filed with the Securities and Exchange Commission.

  • PPD, Inc., a leading global contract research organization, updated its financial guidance for the third quarter ending September 30, 2020.